

**Written Statement of  
Sagar Mehta, MD, The Obesity Society  
before the House Health Committee  
Pennsylvania House of Representatives**

May 23, 2017 Public Hearing on Anti-Obesity Medications

Good morning. I'm Dr. Sagar V. Mehta and I'm Director of Bariatric Medicine at St. Luke's Weight Management Center in Allentown. Today I am speaking on behalf of the The Obesity Society -- the leading professional society dedicated to better understanding, preventing and treating obesity. Through research, education and advocacy, TOS is committed to improving the lives of those affected by the disease.

I appreciate the opportunity to speak before the House Health Committee today regarding anti-obesity medications and obesity treatment in general. Obesity is a multi-factorial chronic disease requiring a comprehensive approach to both prevent and treat. Obesity is associated with a large number of related conditions such as type 2 diabetes, hypertension, heart disease, lipid disorders, certain cancers, sleep apnea, arthritis and mental illness. Therefore, care should not be seen as simply having the goal of reducing body weight, but should additionally be focused on improving overall health and quality of life.

Too often, for too long, private and public health plans have excluded coverage for obesity treatment services -- partly due to shortsighted cost savings efforts and partly due to the false assumption that these services are either not medically necessary, or not in line with generally accepted standards of medical care despite scientific evidence to the contrary.

These discriminatory coverage practices, combined with the growing scientific evidence surrounding obesity, led the American Medical Association (AMA) to declare obesity as a disease in 2013 and subsequently adopt formal policy supporting "patient access to the full continuum of care of evidence-based obesity treatment modalities such as behavioral, pharmaceutical, psychosocial, nutritional, and surgical interventions." Numerous other healthcare professional and patient organizations support the AMA policy because these groups recognize that obesity is associated with, or a precursor to, more than 30 other chronic medical conditions including cardiovascular disease, diabetes, and cancer.

Throughout the last ten years, significant medical advances have been made in the development of obesity drugs. That fact combined with our country's current and growing obesity epidemic, clearly make health plans that continue to exclude coverage for FDA-approved obesity drugs out of date and out of touch with the current scientific evidence surrounding these new pharmaceutical treatments. For example, in the last few years, the FDA has approved four obesity drugs (Belviq, Contrave, Qsymia and Saxenda), and several other promising drugs are quickly progressing through the agency's approval process.

Pennsylvania currently has the 24th highest obesity rate in the country with more than 30 percent of its citizens affected by obesity. It is imperative that the legislature approve HB 899 so that Pennsylvania Medicaid beneficiaries may have access to all evidence-based obesity treatment avenues. Thank you.